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Summary 
The work described in this thesis focuses on the characterization of the 
mechanism(s) underlying the deregulated activation of the intrinsic or mitochondrial 
apoptotic pathway in non-small cell lung cancer (NSCLC) cells. Apoptosis suppression 
might contribute to the chemoresistance often observed in NSCLC patients, and 
elucidation of the molecular causes of this resistance may provide clues for the 
development of targeted apoptosis-based therapies. In this introduction, lung cancer 
and current treatment regimens are described, and mechanisms responsible for 
chemoresistance, in particular towards cisplatin, are summarized. Furthermore, the 
major apoptotic pathways are presented, with a detailed description of the 
mitochondrial apoptotic route and its regulation by Bcl-2 family members and 
inhibitors of apoptosis. Finally, known mechanisms of apoptosis-dependent 
chemoresistance and innovative apoptosis-targeting strategies for cancer therapy are 
discussed. 
  
1. Lung cancer  
 
Lung cancer is the most common cause of cancer death in the world (Jemal et 
al., 2006) with an overall 5-year survival of 15% (Brundage et al., 2002). In the 
United States the epidemiologic estimates for the year 2006 predict that 28 % of all 
cancer death will be due to lung cancer. In men, the incidence of lung cancer has 
decreased appreciably, but it is still the second most commonly diagnosed tumor 
type (92,700 new cases) only surpassed by prostate cancer. Among woman, lung 
cancer incidence continues to increase due to smoking habits (81,770 new cases), 
and is the most commonly diagnosed type of tumor after breast cancer (Wogan et a., 
2004; Jemal et al., 2006). The most predominant cause of lung cancer is cigarette 
smoking, which accounts for over 90% of lung cancer cases (Bray et al., 2004). 
Other factors contributing to the onset of lung cancer are workplace agents, such as 
asbestos, arsenic, chromium, nickel or radon, and also other environmental factors, 
passive smoking, indoor radon and air pollution. The occurrence of lung cancer is 
related to race and socioeconomic status. For example, the mortality due to lung 
cancer among Afro-Americans is higher than among Caucasian Americans. This is 
likely related to a higher exposure to lung cancer  
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risk factors in the first group, such as smoking, diet and inhalation of workplace 
carcinogens (Alberg et al., 2005) and later stage at diagnosis (Schwartz et al., 
2003).  Studies carried out on the role of diet as a potential risk factor for lung 
cancer provided evidence that higher dietary intake of fruits or vegetables is 
correlated with a lower risk of lung cancer (Alberg et al., 1998).  
Lung carcinomas are divided into non-small cell lung carcinomas (NSCLCs) and 
small cell lung carcinomas (SCLCs). NSCLCs are epithelial tumors that represent 
approximately 80% of lung carcinomas, and include three major histological types: 
squamous cell carcinoma, adenocarcinoma and large-cell carcinoma. The remaining 
20% of lung tumors are small-cell carcinomas (SCLCs) that present neuroendocrine 
morphological features (Beasley et al., 2005).  A worldwide tumor-node-metastasis 
(TNM) staging system is used in the management of NSCLCs (Mountain and Dresler, 
1997). This system takes into account the tumor size, the presence of malignant cells 
in regional lymph-nodes, and the presence of distant metastases; stage I to IIA 
represent localized tumors in the absence of metastases, stage IIB to IIIB are locally 
advanced tumors with metastases in lymph nodes, and stage IV is advanced disease 
with distant metastases (see also Table 1). In NSCLC more than three quarters of all 
cases have locally advanced or widespread metastatic disease (stage IIIB and IV) at 
diagnosis. 
SCLCs, on the other hand, are classified according to a simple two-stage system 
developed by the Veteran’s Administration Lung Cancer Study Group (VALCS) (Zelen 
M, 1973). Limited disease is classified as a tumor that can be included in one 
radiation port; extensive disease is beyond these boundaries. Patients with a limited 
disease (LD) represent about 30-40% of SCLCs (Stahel et al., 1989).    
 
1.1. Therapy for lung cancer 
 
Treatment of cancer aims to remove or destroy the cancer cells while sparing 
normal cells. The most common treatment modalities applied in lung cancer are 
surgery for, and/or radiotherapy for localized tumors and chemotherapy for advanced 
or metastatic disease (Minna et al., 2002). Radiation therapy and chemotherapy can 
be applied as an initial treatment (neoadjuvant therapy) with the purpose to shrink 
the tumor for complete resection of borderline respectable tumors (stage III). 
Alternatively, radiation and chemotherapy can be used after surgery for eradication 
of micrometastases (adjuvant chemotherapy) or prevention of local relapse (radiation 
therapy).  
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Table 1. Lung tumor staging (acc. to Mountain, 1997). 
 
 
Stage 
 
Tumor Node 
Metastases 
 
General Description 
Survival 
Rate 
1 Yr    5 Yr 
Local    
 
IA 
 
T1 N0 M0 
 
T1 tumor: ≤ 3 cm, surrounded by lung or pleura; no 
tumor more proximal than lobe bronchus 
 
 
 
94         67 
 
IB 
 
T2 N0 M0 
 
T2 tumor: > 3 cm, involving main bronchus ≥ 2 cm distal 
to carina, invading pleura; atelectasis or invading pleura; 
or pneumonitis extending to hilum, but not entire lung 
 
 
87         57 
 
IIA 
 
T1 N1 M0 
 
N1: involvement of ipsilateral peribronchial or hilar nodes 
and intra- pulmonary nodes by direct extension 
 
 
89         55 
 
Locally 
advanced 
  
 
 
 
 
IIB 
 
T2 N1 M0 
T3 N0 M0 
 
T3 tumor invasion of chest wall, diaphragm, mediastinal 
pleura, pericardium, main bronchus <2 cm distal to 
crania; atelectasis or pneumonitis of entire lung 
 
 
73          39 
 
IIIA 
 
T1 N1 M0 
T2 N2 M0 
T3 N1 M0 
 
T3 N2 M0 
 
N2: involvement of ipsilateral mediastinal or subcranial 
nodes 
N3: involvement of contralateral (lung) nodes or any 
supraclavicular 
 
 
 64          23 
      
 32            3 
 
IIIB 
 
Any T N3 M0 
 
 
 
 
Advanced 
  
 
 
 
 
IIIB 
 
T4 Any N M0 
 
T4 tumor: invasion of mediastinum, heart, great vessels, 
trachea, esophagus, vertebral body, crania: separate 
tumor nodules;  
malignant pleural effusion 
 
 
 
 37          7 
IV Any T Any N M1 Distant metastasis 20          1 
        
Tumor resection provides the best treatment for NSCLC.  The best survival is 
obtained in patients who have pathologically confirmed stage I, and it progressively 
decreases depending on the staging. However, even with complete resection almost 
50% of stage I NSCLC will relapse and die of the disease. The use of adjuvant 
chemotherapy has improved survival of about 5% in patients with stage II and III 
resectable NSCLC (Arriagada et al., 2004). 
Patients with unresectable and metastatic disease may benefit from systemic 
chemotherapy, but the advantage of palliative chemotherapy is only approximately 
an increase of 2 months in median survival. NSCLC is a highly refractory cancer and 
major responses are only obtained in 20-30% of patients and they are short-lived. 
The backbone drugs of chemotherapy on NSCLC are the platinum compounds 
cisplatin and carboplatin (Jamieson and Lippard, 1999). Other chemotherapeutic 
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agents that are often used in doublet combinations with a platinum compound are 
taxanes (paclitaxel and docetaxel), vinca alkaloids (vinorelbine), and gemcitabine 
(Table 2) (Spira and Ettinger, 2004).  
SCLC is a much more chemosensitive tumor than NSCLC, and chemotherapy 
represents the mainstay treatment for this disease. Approximately 20% of patients 
with limited disease can be cured by a concomitant combination of chemotherapy 
and radiotherapy. Surgery is rarely used in SCLC, because of its high propensity to 
develop early and wide spread metastatization, in comparison to NSCLC. 
 
1.2. Chemoresistance of lung cancer 
 
Despite an improved understanding of the molecular biology of lung cancer, and 
significant advances in the treatment, resistance to anticancer therapy is a major 
cause of treatment failure (Minna et al., 2002). Resistance to chemotherapy can be 
intrinsic or acquired. NSCLC is frequently resistant to first-line chemotherapy, and 
the initial response rate amounts to 20-30%. In contrast, SCLC is initially highly 
responsive to anticancer therapy, with 80-90% response rate, but upon relapse, the 
response rate to second-line chemotherapy is very low (Board et al., 2006). 
Furthermore, the problem of multidrug resistance (MDR) arises when tumors develop 
resistance not only towards formerly used drugs, but also towards other cytotoxic 
agents with different structure and mechanism of action (Gottesman et al., 2006). 
Several molecular mechanisms associated with clinical drug resistance have been 
recognized. These mechanisms include alterations in drug transport systems that 
decrease intracellular drug accumulation; metabolic resistance that alters activation 
and inactivation of drugs; alterations of drug-target complexes due to mutations or 
increased levels of drug targets; increased repair of drug induced damage; 
alterations in signalling pathways or drug-induced. Lung tumors may develop 
multidrug resistance and specific resistance to different anticancer agents 
conventionally used in the treatment.    
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Table 2. Current regiments treatment of lung cancer (acc. to Spira, 2004). 
 
 
Type of Study and Group 
 
 
Regimens 
 
 
Conclusions 
 
 
Adjuvant chemotherapy and 
radiotherapy after surgery 
 
 
 
 
 
 
 
 
Addition of chemotherapy to 
radiotherapy in inoperable cancer 
 
 
 
 
 
 
 
 
 
Neoadjuvant chemotherapy in 
stage IIIA diseases 
 
 
 
 
 
 
 
 
 
Neoadjuvant chemotherapy in 
stage I, II or III disease 
 
 
 
 
 
Chemotherapy for advanced 
diseases 
 
Etoposide, cisplatin, and                               
radiotherapy vs. radiotherapy 
alone (Keller et al) 
 
Cisplatin-based adjuvant 
chemotherapy vs. observation 20 
(IALCTCG) 
 
 
 
Cisplatin, vinblastine, and 
radiotherapy vs. radiotherapy 
alone (Dillman et al) 
 
Cisplatin, vinblastine, and 
concurrent radiotherapy vs. 
cisplatin, vinblastine, and 
sequential radiotherapy  
(Curran et al.) 
 
 
 
Etoposide and cisplatin before and 
after surgery vs. surgery and 
radiotherapy (Roth et al.) 
 
Mitomycin, ifosfamide, and 
cisplatin before surgery and 
radiotherapy vs. surgery and 
radiotherapy (Rosell et al.) 
 
 
 
Mitomycin, ifosfamide and cisplatin 
before surgery and radiotherapy 
vs. surgery and radiotherapy 
(Depierre et al.) 
 
 
 
Cisplatin and paclitaxel vs. 
cisplatin, cisplatin and 
gemcitabine, cisplatin and 
docetaxel, and carboplatin and 
paclitaxel  
(Schiller et al.) 
 
 
Carboplatin, paclitaxel, and 
gefitinib vs. carboplatin and 
paclitaxel (Johnson et al.) 
 
No advantage of chemotherapy 
 
 
 
4% absolute increase in overall 
survival with adjuvant chemo-
therapy at 5 yr (p<0.003) 
 
 
 
Increased survival rate at 1, 2, 3, 
and 7 yr with chemotherapy (13% 
vs. 6%) 
 
Increased survival with concurrent 
radiotherapy (p=0.046), but 
increased incidence of esophagitis 
(25% vs. 4%) 
 
 
 
Increased survival with chemo- 
therapy (56% vs. 15% at 3 yr) 
 
 
Increased median survival with 
chemotherapy (26 mo vs. 8mo) 
 
 
 
 
 
No benefits for patients with N2 
disease; small survival advantage 
for patients with N0 or N1 disease 
at 1 and 4 yr 
 
 
 
Results approximately equivalent 
for all regimens; most adverse 
effect with cisplatin and 
gemcitabine, but also slightly 
higher survival rate; least adverse 
effects with carboplatin and 
paclitaxel 
 
No advantage for gefitinib when 
given with standard chemotherapy 
 
 
 
1.2.1. Resistance to cisplatin and carboplatin in NSCLC 
 
Platinum drugs are the most widely used anticancer agents for the treatment 
of human malignances, including ovarian, testicular, bladder, cervical, head and neck 
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and lung carcinomas (Rozencweig et al., 1977). The antineoplastic activity of 
cisplatin relies on its ability to bind to DNA and form different types of adducts 
(Brabec and Kaspasrkova, 2005). The major type of adducts formed by cisplatin are 
1, 2-intrastrand cross-links involving two adjacent bases (cis-GG and cis-AG) that 
comprise 50% and 28% of all formed adducts, respectively. Additionally, 10-13% of 
adducts are 1, 3-intrastrand cross-links involving non-adjacent guanines (cis-GNG) 
and interstrand adducts monofunctionally bound cisplatin to a guanine base 
(Jamieson and Lippard, 1999).  
Cisplatin resistance is multifactorial. Mechanisms of resistance include 
reduced accumulation of the drug, increased intracellular detoxification, increased 
capability to repair cisplatin-DNA damage, and alterations in the induction of 
apoptosis.  
The changes in intracellular accumulation of cisplatin may result from 
decreased cellular uptake or increased cellular efflux of the drug (Gorlik et al., 1997). 
Cisplatin enters the cell by passive diffusion or diffusion dependent on cellular 
membrane potential. Additionally, the ATP-dependent activation of efflux pump 
contributes to cisplatin resistance. Moreover, metallothioneins (MT) and glutathione 
(GSH)-related metabolism enzymes modulate cellular detoxification system. The 
increased expression of MT stress-response proteins that are involved in 
detoxification of heavy metals is associated with various cisplatin-resistant tumors. 
Cisplatin resistance might result from conjugation with GSH followed by inactivation 
of cisplatin or prevention of cisplatin-adducts formation. The level of GST-π 
isoenzyme expression was significantly associated with intrinsic resistance to cisplatin 
in lung cancer cell lines (reviewed in Seve and Dumontet, 2005). 
The resistance to cisplatin/gemcitabine in lung cancer cells may also result 
from enhanced DNA repair (Lord et al., 2002) through .the nucleotide excision repair 
(NER), the transcription-coupled repair (TCR) or the global genomic repair (GGR) 
pathways. Moreover, there are evidences that cisplatin-DNA adducts kill cells by 
induction of programmed cell death, apoptosis (Eastman and Rigas, 1999).Many 
tumor cell types undergo apoptosis in response to DNA-damaging agents (Sedletska 
et al., 2005). For example, sensitive tumor cells treated with cisplatin have 
demonstrated the ability to activate the “caspase cascade” (Gonzalez et al., 2001). It 
has thus been proposed that alterations in the apoptotic program, such as the 
inhibition of caspases, may have a significant contribution to cisplatin resistance in 
tumor cells.  
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In this thesis the main focus was on defining the molecular mechanisms of 
cisplatin resistance in NSCLC cells that are related to the inhibition of apoptotic 
pathways. 
 
2. Apoptosis 
 
Apoptosis is a physiological form of cell death of eukaryotic cells that for the 
first time was described in the 19th century (Vogt, 1842).  In 1972, Kerr and 
colleagues documented this phenomenon by describing the morphological changes 
that occur during apoptosis, such as chromatin condensation, cytoplasmic shrinkage 
and blebbing of the plasma membrane that leads to the formation of “apoptotic 
bodies” (Kerr et al., 1972). Several molecular hallmarks characterize apoptotic cell 
death including, hypercondensation of chromatin, cleavage of chromosomes into 
nucleosomal fragments, and externalization of phosphatidylserine (PS) residues 
(Strasser et al., 2000).  Alterations in the process of apoptosis participate in the 
pathogenesis of a variety of human diseases. For example, enhanced apoptosis is 
involved in AIDS, neurodegradative disorders or ischemic stroke (Thompson, 1995). 
Furthermore, the downregulation of apoptosis has been related to tumor progression 
and the development of chemoresistance (Hanahan and Weinberg, 2000).  
 
2.1.   Apoptosis in tumorigenesis 
 
The accumulation of neoplastic cells can result from enhanced proliferation 
and/or diminished cell death. Inefficient elimination of neoplastic cells might be a 
consequence of alterations in the apoptotic machinery (Kaufmann and Gores, 2000). 
The importance of apoptosis in tumor development was first established based on the 
observation that the Bcl-2 protein, a product of the bcl-2 oncogene, did not enhance 
proliferation, as expected, but promoted cell survival by inhibiting apoptotic cell 
death (Hockenbery et al., 1990).  
An impaired repair of DNA alterations may lead the accumulation of 
mutations, and result in malignant cell transformation (Hanahan and Weinberg, 
2000). However, multicellular organisms have developed mechanisms that protect 
them against the development of cancer. A key player in this protection is the tumor 
suppressor p53 protein, “guardian of the genome” (Levine, 1997). Upon cellular 
stresses, such as DNA damage, hypoxia or aberrant proliferative signals, p53 is 
stabilized and induces either cell cycle arrest or apoptosis (Vousden and Lu, 2002).  
 17 
Thus, p53 protects from the accumulation of oncogenic mutations (Brown and 
Attardi, 2005). The development of multiple cancers is associated with alterations in 
the p53 pathway (Wallace-Brodeur and Lowe, 1999). Loss or disabling of p53-
dependent apoptosis accelerates brain tumorigenesis or promotes lymphomagenesis 
in mice (Symonds et al., 1994; Schmitt et al., 2002).  The p53 protein regulates the 
expression of multiple genes. Among the p53-activated genes there are many that 
modulate the apoptotic machinery. Activation of several Bcl-2 family members is 
dependent on p53. Loss of p53 gene results in loss of Bax expression and causes 
accelerated tumor growth (Yin et al., 1997). The BH3-only proapototic proteins, Noxa 
and PUMA are also activated in a p53-dependent manner. Upon DNA damage caused 
by hypoxia, DNA damaging agents or ER-stress, PUMA induces a very rapid 
apoptosis, but in p53-knockout mice apoptosis was abolished (Villunger et al., 2003). 
Additionally, the Apaf-1 gene is modestly activated by p53 in DNA damage-induced 
apoptosis (Kannan et al., 2001). The p53-dependent apoptosis can also be regulated 
independently on transcription. In this regard, p53 regulates apoptosis outside of the 
nucleus by activation of Bax, or by direct permeabilization of the outer mitochondrial 
membrane and cytochrome c release (Chipuk et al., 2004 and 2005).   
 
 
2.2. Two major pathways of apoptosis 
 
Activation of the apoptotic machinery can be triggered by either of two distinct 
pathways headed by initiator caspase-9 or caspase-8, respectively (Figure 1). The 
intrinsic pathway, which involves activation of caspase-9 in the apoptosome, is 
induced in a mitochondria-dependent manner in response to cellular insults, such as 
chemotherapeutic drugs or UV radiation (Kuida et al., 1998). Activation of the 
extrinsic pathway, led by caspase-8 is initiated by binding of a ligand, such as Fas, 
TNF or TRAIL to cell-surface receptors, termed “death receptors” (DRs). Members of 
the DR family comprise Fas/CD95, tumor necrosis factor-α (TNF-α) receptor-1, and 
the TRAIL receptors DR4 and DR5 (Ashkenazi and Dixit, 1999). Upon ligand binding, 
the adaptor molecule FADD or TRADD is recruited to the intarcellular region of the 
receptor, and binds multiple procaspase-8 zymogens, which results in the activation 
of caspase-8 (Salvesen, 1999). Once activated initiator caspases process and 
activate effector caspase-3 and caspase-7, initiating the demolition phase of 
apoptosis (Creagh and Martin, 2001). The effector caspase-3 can be activated in two 
different ways, and depending on the manner in which caspase-3 is activated, cells 
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can be classified into, type I and II cells. In type I cells activated caspase-8 directly 
cleaves and activates procaspase-3. In type II cells, activation of caspase-8 via death 
receptor is below the threshold that could enable the direct activation of procaspase-
3 (Budihardjo et al., 1999). In these cells, caspase-8 cleaves Bid, a specific 
cytoplasmic proapoptotic member of the Bcl-2 family proteins. Cleaved Bid, called 
truncated Bid (tBid), leads to the disruption of mitochondria and the release of 
apoptogenic co-factors (see below). In this way, there is a crosstalk at the 
premitochondrial level between extrinsic and intrinsic pathways that amplifies the 
apoptotic response (Li et al., 1998).  
 
 
2.2.1. The caspases  
The caspases belong to a family of cysteine proteases that are synthesized 
as single-chain zymogens with an N-terminal prodomain and very low enzymatic 
activity (Nicholson and Thornberry, 1997). Upstream or initiator caspases, caspase-8 
and –9, have large prodomains, and their activation involves both dimerization and 
stabilization. Downstream or effector caspases, such as caspases-3, -6 and –7, have 
short prodomains, and are activated by the initiator caspases through proteolytic 
cleavage (Earnshaw et al., 1999; Boatright and Salvesen, 2003).    
 
Figure 1. Two major apoptotic pathways. 
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Initiator caspase-9  
 
The apical protease of the intrinsic apoptotic pathway, caspase-9, is 
synthesized as a 46kDa zymogen (pro-caspase-9) that is composed of N-terminal 
prodomain, a large subunit (~20kDa/p20), a small subunit (~10kDa/p10), and a 
linker region (LR) between the large and small subunits (Thornberry et al., 1997). 
The long prodomain of caspase-9 contains a crucial protein-protein interaction motif, 
the Caspase Activation and Recruitment Domain (CARD), which is involved in 
formation of protein complexes with another CARD-containing protein, such as Apaf-
1 (Hofmann et al., 1997).  Like other caspases, the processing of caspase-9 occurs 
by cleavage at aspartate residues between the large and small subunits and the 
mature enzyme forms a heterotetramer containing two large and two small subunits. 
Procaspase-9 undergoes either an autocatalytic intrachain processing at Asp315 to 
yield a p35 subunit, or is cleaved at Asp 330 by active caspase-3 to yield a p37 
fragment (Figure 2). Caspase-9 activation is independent on cleavage, and 
processing of caspase-9 does not guarantee its full activation (Stennicke 1999; 
Srinivasula 1998). Only the association of caspase-9 monomers with the adaptor 
protein, Apaf-1 and the dimerization of the caspases ensure its full activation 
(Boatright et al., 2003).    
 
Effector caspases 
 
The downstream caspase-3 and caspase-7 are usually more abundant and 
more active than the initiator caspases, and are thus considered the “workhorses of 
the apoptotic cascade” (Hengartner, 2000). Downstream caspases contain a 
relatively small prodomain, a large (~20kDa/p20) and a small (~10kDa/p10) 
subunits connected via interdomain linker. The role of the prodomain remains poorly 
characterized, but it may be involved in the caspase regulation by cellular 
compartmentalization or spatial sequestration (Meergans et al., 2000). Like initiator 
caspases, effector caspases are also synthesized as single-chain zymogens, but they 
exist in the cytosol as inactive homodimers, which are maintained in a latent state by 
steric hindrances imposed by the interdomain linker (Boatright and Salvesen, 2003). 
Active initiator caspases promote the activation of downstream caspases by cleavage 
of this interdomain linker, followed by translocation of activation loop and formation 
of an active site. The activated effector caspases, in turn, induce processing of many 
cellular substrates (Kaufmann and Hengartner, 2001). 
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2.2.2. Apoptosome 
 
The mammalian apoptosome is a large oligomer containing Apaf-1, caspase-9, 
cytochrome c and dATP (Rodriguez and Lazebnik, 1999). An Apaf-1 heptamer forms 
the scaffold for the apoptosome (Bao and Shi, 2006).  Apaf-1 is a 130kDa protein 
that contains a CARD-interacting domain on its N-terminal part that binds caspase-9, 
a nucleotide-binding domain (NBD) that binds dATP/ATP, and a long C-terminal 
extension composed of 13 WD40 repeats that are involved in the binding of 
cytochrome c (Hu et al., 1998). Within the apoptosome, Apaf-1 and cytochrome c 
coassemble to form a wheel-like structure with seven spokes, where the CARD and 
NBD domains form a central hub (Figure 3) (Acehan et al., 2002; Shi, 2002). The 
assembly of this polymeric platform is a crucial step in the activation of the intrinsic 
apoptotic pathway.  The presence of extra dATP/ATP forces the exchange of dADP 
with dATP, and results in formation of an active apoptosome. Otherwise, an inactive 
aggregate of Apaf-1 is formed (Kim et al., 2005).  
 
Figure 2. Proteolytic processing of caspase-9 and caspase-3 (acc. to Cain et 
al., 2002). 
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Two models describing the mechanism of caspase-9 activation on the apoptosome 
have been proposed. The “allosteric activation” model suggests that the activation of 
single molecule of caspase-9 occurs upon rearrangements of the active site induced 
by interactions with the apoptosome. The “proximity induced dimerization” model, on 
the other hand, proposes that the apoptosome provides a platform to recruit 
caspase-9 and promote its homodimerization due to the increased local concentration 
of the caspase 9 (Boatright et al., 2003, Pop et al., 2006). In the context of the 
dimer, contacts within the catalytic domain of the caspases causes activating 
rearrangements, such as translocation of the activation loop into the accepting 
pocket of the neighbouring monomer (Boatright et al., 2003).  
In addition, the activation of an apical caspase may also be induced through its 
cleavage by effector caspases in a feedback loops. However, such activation may 
only occur when caspase-9 is already present on the apoptosome in a dimeric 
configuration (Cain et al., 2002; Zou et al., 2003).  
 
2.3. Regulation of the intrinsic apoptotic pathway  
 
A crucial step in the intrinsic apoptotic pathway is the permeabilization of 
mitochondria (Armstrong, 2006). This process, termed mitochondrial outer 
membrane permeabilization (MOMP), leads to the release of cytochrome c into the 
cytosol, and constitutes a “point of no return” in the pathway. The pathway can be 
regulated both upstream and downstream of MOMP (Verhagen and Vaux, 2002; 
Green 2003). Regulation upstream of MOMP involves interactions between members 
of the Bcl-2 family of proteins (Coultas and Strasser, 2003; Adams, 2003). 
Downstream of MOMP, another level of regulation is provided by the inhibition of 
active caspases by inhibitors of apoptosis. Finally, caspases are derepressed by 
Smac/DIABLO (Eckelman et al., 2006).  
  
2.3.1. The Bcl-2 family of proteins and the regulation upstream of MOMP 
 
The MOMP is regulated by interactions between Bcl-2 family proteins and the 
targeting of some of them to the mitochondria (Cory and Adams, 2002; Danial and 
Korsmeyer, 2004). This family of proteins is subdivided into three different groups 
based on their antiapoptotic or proapoptotic nature, and on the conservation of the 
Bcl-2 homology (BH1-4) domains (Figure 3). Multidomain antiapoptotic proteins 
include Bcl-2, Bcl-xL, Mcl-1, Bcl-w and Bfl-1/A1. Multidomain proapoptotic members 
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are Bax and Bak. Finally, the BH-3 only proapoptotic proteins are Noxa, Puma, Bid, 
Bim, Bad, Hrk, Bmf, and Bik. Bcl-2 family proteins are regulated at the transcriptional 
level and also through post-translational modifications (Puthalakath and Strasser, 
2002; Kuwana and Newmeyer, 2003).  
The antiapoptotic Bcl-2 proteins prevent the release of apoptogenic proteins, 
such as cytochrome c from mitochondria. On the contrary, the proapoptotic 
members, Bax and Bak induce MOMP and release of cytochrome c (Cheng et al., 
2001; Scorrano and Korsmeyer, 2003).  The BH3-only proteins are the most apical 
regulators of the apoptotic cascade, and are activated upon induction of cell death by 
various internal or external stimuli (Huang and Strasser, 2000).  
A critical mechanism that regulates the activity of Bcl-2 family proteins is 
their oligomerization or heterodimers formation. For example, two proapoptotic 
proteins, such as cytosolic Bax and Bak, a transmembrane protein of the outer 
mitochondrial membrane, undergo conformational changes upon induction by 
cytotoxic signals. Then, Bax translocates to the mitochondria and integrates into the 
outer mitochondrial membrane, where “pore-forming” oligomers of Bax and Bak are 
created, followed by membrane permeabilization (Lucken-Ardjomande and Martinou, 
2005).  BH3-only proteins that contain only one BH domain regulate the activation of 
Bax and Bak (Willis and Adams, 2005). Members of the BH3-only proteins are 
subdivided in two groups. The first group, termed “direct activators” includes Bid and 
Bim, which can directly activate Bax and Bak. The second one, termed “de-
repressors” includes Noxa, PUMA, Bad, Bik, Bmf and Hrk (Letai et al, 2002). The “de-
repressors” are unable to directly activate Bax and Bak, but can sequester the 
antiapoptotic proteins, such as Bcl-2, Bcl-xl and Mcl-1 and release previously 
inhibited proapoptotic Bim and Bid and lead to activation of Bax and Bak (Kuwana et 
al., 2005). This suggests that in the cytosol there are many checkpoints of cellular 
equilibrium, which upon receiving a signal to commit suicide decide whether to 
induce MOMP.  In conclusion, MOMP depends on the regulation of Bcl-2 family 
proteins and the activation of Bax and Bak is a fundamental step initiating the 
mitochondria-dependent cell death.    
 
2.3.2.  The Inhibitors of apoptosis and the regulation downstream of MOMP 
The intrinsic apoptosis pathway can be negatively regulated by direct interactions 
between processed caspases and inhibitory proteins (Deveraux et al., 1998; Salvesen 
and Duckett, 2002). The presence of a CARD domain on procaspase-9 enables 
interactions with other CARD-containing proteins, including TUCAN 
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(CARD8/CARDINAL) (Damiano and Reed, 2004). TUCAN has been proposed to 
selectively suppress apoptosis by interfering with binding of Apaf-1 to procaspase-9 
(Pathan et al, 2001). However, other evidence 
 
Figure 3. The Bcl-2 family proteins 
 
 
suggests that there is no direct interaction between caspase-9 and TUCAN.  In 
addition, downregulation of TUCAN did not sensitize some tumor cells to 
chemotherapeutic agents (Bouchier-Hayes et al, 2001; Checinska et al, 2006). 
TUCAN was also shown to regulate activation of caspase-1 in the THP-1 monocytic 
cell line and stable overexpression of TUCAN sensitized cells to apoptosis (Razmara et 
al., 2002). Studies conducted in lung and colon cancer specimens revealed that 
overexpression of TUCAN correlated with shorter patients’ survival (Pathan et al, 
2001; Krajewska et al., 2005; Checinska et al., 2006). In addition to its proposed 
antiapoptotic role, TUCAN has been reported to potently suppress NF-kB activation 
via interactions with IKK gamma and DRAL (Bouchier-Hayes et al, 2001; Stilo et al., 
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2002). Thus, the regulation of NF-kB pathway by TUCAN points to a more complex, 
role of this protein in tumor biology than as a direct inhibitor of caspases.       
A better-characterized group of apoptotic regulators downstream of MOM is 
the inhibitor of apoptosis proteins (IAPs). IAPs were initially identified in 
baculoviruses and demonstrated the ability to inhibit insect-cell apoptosis after viral 
infection (Crook 1993). In mammalian cells, eight IAPs have been so far identified: 
XIAP, cIAP-1, cIAP-2, Survivin, ML-IAP/Livin, Apollon/BRUCE, ILP2, and NAIP 
(Deveraux and Reed, 1999). The IAPs family proteins members are characterized by 
the presence of one to three baculovirus IAP repeat (BIR) domains (Hinds et al., 
1999). In addition to the BIR motifs, some IAPs contain a C-terminal zinc-binding 
RING domain, which might enable IAPs to polyubiquitylate caspases and target them 
for degradation by the proteasome (Yang et al., 2000).  The cIAP-1 and -2 also 
contain a caspase activation recruitment domain (CARD), but the functional role of 
this domain    remains unclear. Depending on the presence or absence of the BIR or 
RING domains the IAP proteins are divided into three classes (Figure 4) (Schimmer, 
2004). The first class of IAPs includes X-linked IAP (XIAP), cIAP-1 and -2, ILP2 and 
ML-IAP/Livin. All these proteins contain one or three BIR domains, one RING motif, 
and in the case of cIAP-1 and -2 also a CARD motif. In the second-class, NAIP 
contains three BIR domains and a nucleotide binding motif (NB), but no RING finger 
(Roy et al., 1995; Maier et al., 2002). To the third class belong the largest and the 
smallest IAPs, Bruce/Apollon, and Survivin. Bruce/Apollon is an ubiquitin-conjugating 
enzyme (UBC) which ubiquitylates and facilitates proteasomal degradation of 
caspase-9 (Hao et al., 2004). The mechanism by which Survivin regulates apoptosis 
remains controversial (Banks, 2000). 
The best characterized of mammalian IAPs is XIAP, which binds and inhibits 
processed caspases-3, -7 and –9 (Shiozaki et al., 2003; Scott et al., 2005). The 
processed caspase-9 monomer can be inhibited by XIAP via interactions between its 
BIR3 domain and the conserved IAP-binding tetrapeptide motif of the caspase. Other 
weaker interactions also seem to be essential for the efficient inhibition (Sun et al., 
2000). XIAP-mediated inactivation of caspase-9 does not physically involve the active 
site of the caspase. Instead, the IAP traps the caspase and maintains it in an inactive 
state due to the absence of a supporting fragment that would be provided by caspase 
homodimerization (Shi, 2002).  
On the other hand, the homodimers of caspases-3 and -7 once activated are 
vulnerable to inhibition by IAPs, particularly XIAP (Eckelman et al., 2006). The linker 
region preceding XIAP BIR2 interacts with these caspases. Inhibition of caspases-3 
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and -7 happens through steric hindrance, and has been described using a “hook, line 
and sinker” simile. The “hook”, the N-terminal part of XIAP blocks the substrate-
binding pocket of active caspases-3 or -7, the “line” connects the “hook” and the 
“sinker”, which is responsible for the stabilization of the IAP-caspase interaction 
(Schimmer, 2004). 
 
Figure 4. Inhibitors of apoptosis. 
 
Besides XIAP, cIAP1 and cIAP2 have been reported to inhibit caspases. 
However, although cIAP-1 and -2 can bind to caspase-9, they lack the four residues 
necessary to keep the caspase in a catalytically inactive state (Shiozaki et al., 2003; 
Eckelman and Salvesen, 2006). On the other hand, although effector caspases can 
be blocked by direct interactions with cIAP-1 and -2, the inhibition is approximately 
100-fold weaker than that caused by XIAP. Thus, these IAPs are considered as poor 
inhibitors of caspases (Deveraux and Reed 1999; Eckelman and Salvesen, 2006).  
Besides direct caspase inhibition, IAPs may regulate apoptosis through 
different mechanisms. For example, some IAPs are able to polyubiquitylate proteins, 
which interact with them, e.g. caspases or IAPs themselves, and mediate their 
degradation by targeting to the 26S proteasome (Yang et al., 2000, Lorick et al., 
1999). Finally, in addition to their role in apoptosis, certain IAPs can regulate cell 
cycle progression (Levkau et al., 2001), cell division (Uren et al., 1999) and signal 
transduction (Sanna et al., 2002).    
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Smac/DIABLO is an endogenous de-repressor of caspases, which counteracts the 
inhibitory effect of IAPs (Du et al., 2000). Smac is a 293 amino acid mitochondrial 
protein that is released into the cytosol along with cytochrome c upon MOMP (Chai et 
al., 2000). In the cytosol, Smac undergoes  
maturation by proteolytic cleavage of its N-terminal part, which exposes an AVPI 
tetrapeptide motif. Through this motif Smac can interact with the BIR2 and BIR3 
domains of XIAP (Liu et al., 2000). Smac binding to XIAP BIR3 prevents XIAP from 
binding to caspase-9 (Chai et al., 2000; Srinivasula et al., 2001).  The AVPI motif of 
SMAC may also bind the BIR2 domain of XIAP, removing the inhibition of effector 
caspases. However, the affinity for BIR2 is ~10-fold lower than for BIR3.The 
molecular mechanism by which Smac disrupts the binding between XIAP and 
downstream caspases still remains elusive, but seems to involve steric hindrance 
rather that competitive binding (Chai et al., 2000; Fesik and Shi, 2001). 
 
2.4. Apoptosis and chemoresistance 
 
Resistance to anti-cancer agents is an important and unresolved clinical 
problem. Multidrug resistance may result from molecular alterations in drug efflux 
pumps and from inhibition of drug-target interactions. However, since drug-induced 
damage might initiate the activation of apoptosis as a secondary response, there are 
evidences for significant contribution of apoptotic defects in multidrug resistance 
(Johnstone et al., 2002; Siddik, 2003). 
Apoptosis may be disrupted through the inhibition of the p53 pathway (Lowe 
et al., 1993).  The p53 tumor suppressor gene is the most frequently mutated gene 
in human tumors and the loss of p53 function was shown to impair apoptosis in 
transgenic mice (Attardi and Jacks, 1999). However, the presence of wild-type p53 
does not guarantee that cells undergo efficient apoptotic death (Schmitt et al., 
1999). The disruption of mitochondria-dependent pathway is a frequent cause of 
drug resistance in various tumors. It can be caused by altered expression or 
mutations of Bcl-2 family members (Reed, 1995). Several clinical studies 
demonstrated that overexpression of Bcl-2 correlates with a poor prognosis (Catlett-
Falcone et al., 1999). Moreover, overexpression of antiapoptotic Bcl-2 protein in an 
extensive panel of cancer cell lines exposed to different anticancer drugs was 
accompanied by inhibition of apoptosis (Yang and Korsmeyer 1996; Larochette et al., 
1999; Johnstone et al., 2002). Another antiapototic protein, Bcl-xL, also seems to 
promote drug resistance by induction of cell survival (Simonian et al., 1997). Bcl-Xl 
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overexpression is associated with a poor outcome in patients with lymphomas, 
oropharynx carcinoma or soft-tissues sarcomas (Bairey et al., 1999; Aebersold et al., 
2001; Kohler et al., 2002).  
The alterations in the expression of proapoptotic Bcl-2 family members may 
also result in development of drug resistance. In vitro studies showed that Bax 
deletion blocked drug-induced apoptosis in a colon carcinoma cell line (Zhang et al., 
2000). On the contrary, in fibroblasts the single deficiency for either Bax or Bak did 
not alter apoptosis response, but lack of both of them induced defective mitochondria 
stress-dependent apoptosis (Wei et al., 2001).  
Apoptosis may also be disturbed downstream of the mitochondria, at the 
level of the apoptosome. The Apaf-1 protein seems to have a crucial implication in 
the response to drug-induced apoptosis in melanoma cell lines and clinical 
specimens. Apaf-1 deficient melanoma cells showed decreased apoptosis in response 
to doxorubicin (Soengas et al., 2001; Fernandez et al., 2005; Soengas et al, 2006). 
However, other studies have found that a lack of Apaf-1 expression does not 
necessarily correlate with inhibition of apoptosis, and may depend on the treatment 
regimens (Allen et al, 2005; Petlenburg et al., 2005). Additionally, the intrinsic 
apoptotic route might be altered by inhibition caused by endogenous suppressors of 
caspases, such as IAPs. The presence of excess levels of XIAP, cIAP-1 and cIAP-2 
may cause blockage of initiator and effector caspases, and inhibit drug-induced 
apoptosis.  IAPs are frequently overexpressed in cancer cells, and their elevated level 
is associated with chemoresistance (Ekedahl et al., 2002). Several studies have 
shown that XIAP downregulation by antisense oligonucleotide sensitizes cells to drug-
induced apoptosis (Hu et al., 2003). However, cIAP-1 and cIAP-2 seem to play rather 
a minor role in apoptosis-dependent chemoresistance (Eckelman and Salvesen, 
2006).  
In summary, postmitochondrial alterations in cancer appear to be less 
common than defects upstream of mitochondria involving Bcl-2 family proteins. This 
would explain the fact that apoptosis can still occur in the presence of IAPs (Herr and 
Debatin 2001). Since alterations in the regulation of apoptosis contribute to cancer 
development, the restoration of the disturbed balance between cell proliferation and 
cell death may contribute to effective cancer treatment. Thus, proteins involved in 
apoptosis pathways are promising targets for cancer drug discovery, as described 
below.   
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2.5 Apoptosis-based therapy of cancer 
 
The primary aim of targeted cancer therapy is to block the growth and spread 
of malignant tumor cells without damaging surrounding healthy cells. New generation 
drugs can recognize specific targets in or on tumor cells and act specifically against 
them. Targeted agents can be applied alone, or in combination with other targeted 
drugs, or with traditional chemotherapy. An increasing number of targeted agents 
are being approved for the treatment of several cancer types (Segota and Bukowski, 
2004).  
Malignant cells can be targeted by different approaches. Two major 
approaches are monoclonal antibodies and low molecular weight chemical molecules. 
Monoclonal antibodies can be conjugated to specifically deliver chemotherapeutic or 
radioactive agents, mark tumor cells for elimination by the immune system, and to 
inhibit membrane receptors.  Small molecules might be used to modulate signaling 
pathways responsible for tumor cell proliferation and growth and they may target 
intracellular proteins more effectively than monoclonal antibodies (Fischer and 
Schulze-Osthoff, 2005).  
Several components of the cell death machinery are attractive targets for 
direct promotion of apoptosis (Reed, 2006). These include the tumor necrosis factor 
(TNF), TNF-related apoptosis-inducing ligand (TRAIL) (Buchsbaum et al, 2006), the 
anti-apoptotic or pro-apoptotic Bcl-2 family members (Papadopoulos, 2006), the 
caspases, the inhibitors of apoptosis (IAPs), and Smac/DIABLO (Table 3) (Reed, 
2003; Fischer and Schulze-Osthoff, 2005).  
 
 
 
2.5.1. Therapeutic targeting of Tumor Necrosis Factor (TNF) and TNF-
Related Apoptosis-Inducing Ligand (TRAIL) 
 
The extrinsic apoptotic pathway is activated via the tumor necrosis factor 
(TNF) receptor superfamily upon binding a ligand, such as TNF-α, CD95 ligand or 
TNF-related apoptosis-inducing ligand (TRAIL). Ligand binding is  
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Table 3. Apoptosis-based therapeutics (acc. to Fischer, 2005).   
 
 
Death receptors 
TRAIL receptor 
 
 
 
 
 
 
 
 
 
 
TNF 
 
 
 
Caspases 
Pan-caspase 
 
 
 
 
Caspase-3 
 
 
 
 
 
 
 
 
 
 
Caspase-9 
 
 
 
IAPs and Smac 
XIAP 
 
IAPs and Smac 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Smac 
 
 
 
Bcl-2 proteins 
 
 
 
 
 
 
 
HGS-ERT 1 
 
 
HGS-ERT2 
 
 
HGS-TR2J 
 
 
PRO 1762 
 
 
Recombinant 
TNF-α 
 
 
Small-molecule 
compounds 
 
RGD peptides 
 
 
Immunocaspase
-3 
 
 
Ad-G/iCasp3 
 
 
 
PEF-F8-CP3 
 
 
FKBP12/caspase
-9 fusion protein 
 
 
BIR3 antagonists 
 
 
Capped 
tripeptide XIAP 
antagonist 
 
TWX024 
 
 
 
 
Polyphenylurea  
derivatives 
 
 
XIAP antisense 
and RNAi 
constructs 
 
 
AEG35156 
 
 
 
 
Smac-mimetic 
compound 
 
 
Bcl-2 blocker 
 
 
Antimycin A 
derivatives 
 
 
Synthetic 
Compound 
binding to the 
BH3 domain of 
Bcl-2 
 
 
Agonistic TRAIL-R1 mAB 
 
 
Agonistic TRAIL-R2 mAB 
 
 
Agonistic TRAIL-R2 mAB 
 
 
Soluble human Apo2L/TRAIL 
 
 
Combination of TNF and 
chemotherapy 
 
 
Caspase activators 
 
 
Caspase activators 
 
 
Cell-permeable HER2 mAb 
fused to caspase-3 
 
 
Adenoviral chemically 
inducible caspase-3 
 
 
Caspase-3 fusion construct 
with single-chain 
 
Chemically inducible 
dimerization of 
caspase-9 
 
Small-molecule antagonist of 
IAPs 
 
BIR3 ligand of XIAP 
 
 
 
Nonpeptidic small-molecule 
inhibitor of BIR2/caspase-3 
interactions 
 
 
BIR-2-specific nonpeptidic 
inhibitors100 
 
 
Inhibitor of XIAP expression 
 
 
 
 
XIAP antisense 
oligonucleotide 
 
 
 
XIAP-binding Smac-mimetic 
compound 
 
 
Small molecule inhibitors of 
Bcl-2/Bcl-xL 
 
Natural and synthetic 
Bcl-2/Bcl-xL inhibitors 
 
 
Bcl-2 18mer antisense 
oligonucleotide 
 
 
 
 
Apoptosis induction in tumor 
cell lines and mouse model 
 
Apoptosis induction in tumor 
cell lines 
 
Apoptosis induction in tumor 
cell lines 
 
Apoptosis induction in tumor 
cell lines 
 
Apoptosis induction in 
tumor-associated blood 
vessels 
 
Activation of caspases solely 
in tumor cells 
 
Induction of apoptosis in 
cancer cells 
 
Growth inhibition of HER2-
positive tumors in a mouse 
xenograft model 
 
Reduction in tumor growth 
inducible caspase-3 
 
 
Antigen-dependent induction 
apoptosis 
 
Anti-angiogenic in mouse 
model upon induction of 
caspase-9 dimerization 
 
Proapoptotic in tumor cell 
lines 
 
Antitumor activity in 
breast cancer mouse model 
 
 
Prevent XIAP/caspase-3 
interactions in vitro, 
synergistic with anti-CD95 
and TRAIL 
 
Direct activation of caspases 
xenografts tumor growth 
suppression 
 
Induce apoptosis 
in vitro synergistic with 
chemotherapy 
in mouse model 
 
Tumor growth suppression in    
combination with 
chemotherapy 
in mouse model 
 
Enhanced cisplatin-induced 
apoptosis in prostate cancer 
cells 
 
Apoptosis induction in tumor 
cells 
 
Bind to BH3 pocket of Bcl-2 
and Bcl-xL and induce 
apoptosis 
 
Kills drug-resistant chronic 
lymphocytic    leukemia cells 
delays development of fatal 
lymphoma in mice, increases 
dacarbazine effectiveness in 
melanoma model 
 
 
 
Phase 2 
 
 
Phase 1 
 
 
Phase 1 
 
 
Phase 1 
 
 
Approved for 
melanoma 
therapy 
 
Preclinical 
 
 
Preclinical 
 
 
Preclinical 
 
 
 
Preclinical 
 
 
 
Preclinical 
 
 
Preclinical 
 
 
 
Preclinical 
 
 
Preclinical 
 
 
 
Preclinical 
 
 
 
 
Preclinical 
 
 
 
 
Preclinical 
 
 
 
Phase1 
 
 
 
 
Preclinical 
 
 
 
Preclinical 
 
 
Preclinical 
 
 
 
Phase 3 for 
NSCLC 
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followed by formation of the death-inducing signaling complex (DISC), which recruits 
and leads to the activation of caspase-8 or –10, and the subsequent cleavage-
mediated activation of downstream caspases (Fulda and Debatin, 2006). Despite the 
exciting perspectives resulting from preclinical studies with TNF and CD95 agonists, 
these compounds could not be used in clinical trials because of severe hepatic 
toxicity (Daniel et al., 2001). However, TNF was able to destroy blood vessels of the 
tumor, and improve their permeability to chemotherapeutics. In locally advanced 
melanoma and sarcoma the delivery of high-dose TNF with chemotherapy has 
significant activity when given by limb perfusion technique (Eggermont et al., 2001; 
Curnis et al., 2000).  
Triggering the TRAIL receptor seems to be a more promising approach, given 
that TRAIL ligand specifically damages cancer cells, but spares healthy cells 
(Ichikawa et al., 2001). Agonistic TRAIL-R1 or TRAIL-R2 monoclonal antibodies and 
soluble human Apo2L/TRAIL are currently being evaluated (Menoret et al., 2006, 
Marini et al., 2006). The apoptosis induction in a broad range of cancer cell lines and 
xenografts models, the lack of side effects in non-human primates and mice, and 
synergism with conventional chemotherapeutics led to phase I and II clinical trials 
(Lawrence et al., 2001). Hints of activity have been shown by this therapeutics 
alone; however a higher efficacy is expected by combination with chemotherapy or 
other agents that stimulate apoptosis via different pathways (Fischer and Schulze-
Osthoff, 2005).  
 
2.5.2. Therapeutic targeting of Bcl-2 family members 
 
Anti-apoptotic Bcl-2 proteins are overexpressed in many cancers, including 
melanoma, lung, pancreatic, ovarian, prostate cancer and are associated with 
resistance to conventional chemo-and radiotherapy. Therefore, the anti-apoptotic 
Bcl-2 members are attractive targets for anticancer therapy.  
Two different approaches have been applied to target Bcl-2, Bcl-xl and Mcl-1. 
Antisense oligonucleotides or BH3 domain peptides are able to knockdown these 
proteins and, on the other hand, small molecule drugs will interfere with complex 
formation of anti- or proapoptotic Bcl-2 family members (Fischer, 2005).  
Using antisense oligonucleotides, a reduction of the expression levels of Bcl-
2 protein can be achieved. A 20-mer anti-Bcl2 oligonucleotide has been shown to 
induce or enhance apoptotic cell death in lymphoma or leukemia cells when applied 
alone or in combination with chemotherapeutic agents (Reed et al., 1990). Another 
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18-mer antisense oligonucleotide targeting Bcl-2 (oblimersen/genasense) (Frankel 
2003) showed highly synergistic effects in combination with standard chemotherapy 
in a preclinical study performed in a xenograft breast cancer model (Chi et al., 2001; 
Klasa et al., 2002). Therefore, oblimersen was introduced in clinical trials, but it 
failed to meet a primary end-point of increasing survival in phase III trial in 
malignant melanoma and in refractory multiple myeloma. However, patients with 
chronic lymphocytic leukaemia (CLL) treated with oblimersen and traditional 
chemotherapy, e.g. fludarabine and cyclophosphamide showed improved overall 
response rate and thus, phase III trails with oblimersen were approved (Koziner, 
2004). Similarly, phase III studies for non-small cell lung and phase II for hormone 
refractory prostate cancers have been initiated (Herbst and Frankel, 2004). 
A different approach was used to regulate the level of Bcl-x proteins. Two 
forms of Bcl-x protein result from alternative splicing, pro-apoptotic Bcl-xs and 
antiapoptotic Bcl-xl. Making use of this property of Bcl-x, the splicing machinery was 
targeted to redirect Bcl-x mRNA processing into proapoptotic Bcl-xs, instead of using 
antisense oligonucleotides to knockdown Bcl-xl expression (Taylor et al., 1999). 
 Importantly, optimal results appear to be achieved by simultaneous 
downregulation of Bcl-2 and Bcl-xl proteins. Indeed, the bispecific Bcl-2/Bcl-xl 
antisense oligonucleotides showed to be effective in preclinical studies performed in 
many cancer cell lines (Zangemeister-Wittke et al., 2000; Millela et al., 2004).  
Since the anti-apoptotic Bcl-2 proteins form complexes with proapoptotic 
BH3-only protein, their function can be inhibited for therapeutic purposes by 
employing peptides or small molecules mimicking the BH3 domain (Willis et al., 
2005). A preclinical in vitro study demonstrated that BH3 peptides promote the 
disruption of Bax/Bcl-2 complexes, which was followed by the release of cytochrome 
c and apoptosis (Willis et al., 2005). Several strategies have been employed to 
improve the cellular permeability of BH3 peptides and direct them to the membrane. 
The first approach uses coupling of BH3 proteins to transduction domain, conjunction 
to fatty acids or delivery by cationic lipids. Encouraging results came from a study in 
human leukemic cell lines and mice with leukemia, where cell-permeable BID-based 
BH3-peptide mimetics, termed SAHBs (stabilized alfa-helix f Bcl-2domains), 
efficiently induced apoptosis (Walensky et al., 2004).  Studies performed by Letai 
and co-workers showed that Bad- and Bik- based BH3 peptides bind to Bcl-2 and 
promote dislocation of bound proapoptotic proteins (Letai et al., 2002). The second 
approach involves non-peptidic organic compounds derived from Bid and Bim BH3 
that promoted oligomerization of Bax and Bak. The structure-based designing of 
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these compounds guarantees efficient binding in micro- or nanomolar range to Bcl-2, 
Bcl-xl and Bcl-w proteins, and induction of apoptosis (Real et al., 2004; Wang et al., 
2000). Some of these compounds, such as Gossypol, are being evaluated in phase I 
clinical trials in CLL patients (Mohammad et al., 2005). More recently, a Bad-based 
BH-3 compound, termed ABT-737, has demonstrated synergistic effect with chemo- 
and radiotherapy in a broad range of cancer cell lines. Furthermore, it, has shown 
apoptotic activity as a single agent in lymphoma and leukemia cell lines and primary 
cells, and induced complete regression of SCLC tumor xenografts in mouse 
(Oltersdorf et al., 2005).  
In summary, antisense oligonucleotides against anti-apoptotic Bcl-2 family 
and BH3-mimic peptides or small molecules displayed impressive therapeutic 
potential in preclinical studies Therefore, the improvement of these strategies to 
efficiently induce apoptosis has an enormous potential in cancer therapy.  
 
2.5.3. Therapeutic targeting of caspases 
 
“Turning on” the death machinery by activation of initiator or effector 
caspases, may be a suitable approach for cancer therapy (Hengartner, 2000). Thus, 
adenoviral vectors expressing chimeric inducible caspase-3 and -9 were specifically 
targeted to prostate cancer cells and demonstrated rapid killing of cancer cells 
(MacCorkle et al., 1998; Shariat et al., 2001; Xie et al., 2001).  On the other hand, 
since many tumors of different type, overexpress the erbB2/HER2 receptor novel a 
chimeric protein composed of anti-HER2-antibody linked to caspase-3 has been 
engineered and is currently being evaluated in the clinic (Jia et al., 2003). Another 
approach for the caspase-based therapy of cancer relies on the use of small cell-
permeable drugs that are able to activate cellular caspases. For example, 
procaspase-3 contains the DDM tripeptide sequence near the active site, which keeps 
the enzyme in a dormant state. There is evidence that arginine-glycine-aspartate 
(RGD) synthetic peptides may interact with the DDM motif and promote catalytic 
activation of caspase-3 (Roy et al., 2001).  RGD peptides are already in clinical trials 
for inhibition of tumor blood vessels formation, but their ability to induce caspase-3 
activation could add to their therapeutic potential (Buckley et al., 1999). 
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2.5.4. Therapeutic targeting of Inhibitors of apoptosis (IAPs) 
 
  Given their function as negative regulators of apoptosis, the inhibition of 
IAPs, particularly XIAP, could provide substantial benefits for anti-cancer targeted 
therapy. Knockdown of XIAP protein using antisense oligonucleotides or RNA 
interference approach promoted apoptosis and synergistic killing effect of TRAIL or 
actimomycin D on cancer cells (Bilim et al., 2003; MacManus et al., 2004). The 
second-generation XIAP antisense oligonucleotide, AEG35156 /GEM® 640 
demonstrated significant efficacy in preclinical studies and is currently evaluated in 
clinical trials (LaCasse et al., 2006). Additionally, several agents that target XIAP BIR 
domains are been testing in preclinical studies. Thus, a BIR3 antagonist showed 
proapototic and antitumor activity in tumor cells and breast cancer xenograft models 
(Oost et al., 2004). On the other hand, non-peptidic BIR2 inhibitors, e.g. 
polyphenylurea derivates, revealed proapototic activity and growth suppression of 
implanted tumors (Schimmer, 2004).  
Encouraging results have been also obtained with Smac peptides or Smac-
mimetic drugs that enhanced apoptotic effects of chemotherapeutic agents in vitro 
and in vivo (Arnt et al., 2002; Bockbrader et al., 2005). Smac peptidomimetics 
potently induced caspase activation, which was followed by apoptotic cell death in 
prostate cell lines, but also in xenografts mouse models of human glioma and NSCLC 
exposed to TRAIL or DNA-damaging agents, respectively (Fulda et al., 2002; Yang et 
al., 2003). Similarly, nonpeptidic Smac-mimetic compounds were capable of 
enhancing caspase-3 activation and potentiate cisplatin-induced cell death in human 
prostate cancer cells, or in glioblastoma cells exposed to TNF or TRAIL (Li et al., 
2004; Sun et al., 2004).  
 
 
 
3. Proteasome Inhibitors in Treatment of Lung Cancer 
 
  The proteasome inhibition is a novel promising therapeutic approach that has 
been evaluated in a number of cancers, including lung cancer (Lara et al., 2004). 
Proteasome inhibitors very efficiently disrupt degradation of intracellular proteins via 
the ubiquitin-proteasome pathway (Adams et al., 1999). A broad range of 
proteasome inhibitors has been analyzed, but only peptide aldehydes MG132 and 
CEP1612 have been screened in vitro and in vivo in preclinical studies in lung cancer 
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cell lines (Sun et al., 2001; Bang et al., 2004). The most effective, metabolically 
stable and more specific to the 26S proteasome is Bortezomib/PS341/Velcade a 
boronate peptide (Teicher et al., 1999). Bortezomib has been investigated as a single 
agent in many preclinical studies, and as a single-agent or in combination regimens 
in phase I and II clinical studies in lung cancer (Scagliotti, 2006). In preclinical 
studies, bortezomib proved to be a very potent apoptosis-inducing drug, which 
promotes a production of reactive oxygen species or regulates the balance between 
Bcl-2 family members (Ling et al., 2003). Bortezomib-mediated proteasome 
inhibition caused the blockage of the NF-kB pathway, which was followed by 
downregulation of Bcl-2 and promotion of apoptosis (Fahy et al., 2005; Mortenson et 
al., 2005). Studies conducted in a mouse model identified additional benefits form 
bortezomib treatment, such as a delay of tumor growth, and a reduction in the 
number of lung metastases (Teicher et al., 1999). Interestingly, positive results have 
been obtained from studies where bortezomib was used in combination regimens 
with anticancer agents, including carboplatin and gemcitabine (Mortenson et al., 
2004). In vitro and in vivo studies revealed massive induction of apoptotic cell death, 
and significant reduction of the tumor size. The successful preclinical results of 
bortezomib encouraged introducing this agent in clinical trials. So far, bortezomib is 
the only proteasome inhibitor evaluated in lung cancer patients (Aghajanian et al., 
2002). Phase I and II clinical studies were performed in patients with advanced 
NSCLC using bortezomib in monotherapy and combination therapy with docetaxel or 
gemcitabine, and some patients showed partial response and stable disease (Davies 
et al., 2004; Fannucchi et al., 2005).  
 
4. Outline of the thesis 
 
In the introduction of this thesis, Chapter 1, general information about lung 
cancer and its resistance to currently used drug regimens are presented. Particular 
emphasis is put on the relations between the regulation of mitochondria-dependent 
apoptosis and tumorigenesis or chemoresistance.  An outline of the conventional 
therapies against lung cancer is described, with an overview of recent advances in 
the field of preclinical and clinical apoptosis-based therapies. The principal aims of 
this thesis were to investigate the molecular mechanism(s) that regulate the 
suppression of caspases in the mitochondria-dependent apoptotic pathway in NSCLC 
cells, and to assess the benefits of apoptosis-based therapy in improving an efficacy 
of conventional chemotherapy.  
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Inhibition of caspase-9, which is involved in mitochondria-dependent pathway 
of apoptosis, contributes to the resistance to chemotherapy in NSCLC cells. In 
Chapter 2 we have investigated whether the inhibition of caspase-9 is caused by the 
presence of the negative regulator of apoptosis TUCAN /CARDINAL /CARD8, which 
might block caspase-9 activation. In Chapter 3 we determined the expression of 
TUCAN protein in specimens from patients with advanced NSCLC, and showed that 
differential localization of TUCAN seems to have a prognostic value for NSCLC. Since 
the preclinical study revealed that TUCAN do not play a role in inhibition of caspase-9 
in NSCLC and the most potent inhibitor of apoptosis, XIAP that was overexpressed in 
this tumor type, we investigated in Chapter 4 whether XIAP is involved in the 
suppressing of caspase-9-headed apoptosis. We attempted to explore the potential 
therapeutic benefits of Smac mimic molecules in combination treatment with DNA-
damaging agents in NSCLC cells.  Activation of caspase-9 and an increase of 
apoptotic cell death were observed upon exposure of NSCLC cells to bortezomib, a 
novel proteasome inhibitor. In Chapter 5, we focused on the molecular mechanism 
of action of bortezomib, which in contrast to cisplatin was able to efficiently promote 
a proapoptotic shift of the levels of Bcl-2 family proteins, which was followed by 
cytochrome c release.     
Chapter 6 describes the results of a tandem mass spectrometry (MS)-based 
proteomics analysis of protein complexes associated with caspase-9 in NSCLC cells, 
under experimental conditions in which the caspase is free or recruited to the 
apoptosome. Our goal was to identify novel potential inhibitory proteins of the 
mitochondria-dependent apoptotic pathway.  
Finally, the results and main findings of this thesis and their possible clinical 
implications are discussed in Chapter 7.   
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